Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825600 | 0.89 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL28528205 | 0.82 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL13712371 | 0.82 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL401725 | 0.80 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29367495 | 0.80 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL31031957 | 0.80 | KMT2A (0.67) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL4612352 | 0.80 | KMT2A (0.58) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL7267676 | 0.80 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL9283053 | 0.80 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL21332462 | 0.80 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | KMT2A 1292/4885EPHX2 1857/4885CASP3 376/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | KMT2A 1292/4885EPHX2 1857/4885CASP3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.